DMG-PEG1000-iRGD

DMG-PEG1000-iRGD is specifically designed for active targeting nanomedicine applications. It can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against sequential binding to αv integrins on tumor vasculature → neuropilin-1 (NRP1) in tumor tissue.
Composition and role of each component:
1. DMG (dimyristoylglycerol): Lipid anchoring group-a diacylglycerol with two C14 chains, providing moderate membrane anchorage; its short-chain, high-fluidity characteristics enable faster dissociation of PEG-lipids from nanoparticle surfaces, facilitating endosomal escape and cellular uptake.
2. PEG1000 (polyethylene glycol, MW 1000): Hydrophilic polymer spacer arm that forms a steric corona around nanoparticles, reducing opsonization and reticuloendothelial system (RES) clearance, prolonging circulation half-life, and providing spatial separation between the lipid surface and targeting ligand.
3. iRGD (iRGD peptide (CRGDK/RGPD/EC)): Targeting ligand-a tumor-homing and penetrating peptide that combines an RGD motif (for αv integrin binding) with a C-end rule (CendR) sequence. Upon binding to αv integrins on tumor vasculature, the peptide is proteolytically processed to expose the CendR motif, triggering neuropilin-1 (NRP1)-mediated tissue penetration. This dual mechanism enables deep penetration into tumor tissue beyond the vasculature.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.